Maynard was electrocuted on a railway line and then struck by a train as he attempted to flee police after driving on a cocktail of drink and drugs last June.
The inquest at Westminster Coroners' Court on Tuesday heard that a post-mortem examination showed 23-year-old Maynard was nearly four times the legal limit to drive. Maynard had also taken cocaine and ecstasy after a night out with his two flatmates in Wandsworth, south London, and the inquest passed a verdict of accidental death.
An ECB statement said: "While the ECB accepts that recreational drug use is a part of modern society, we do not condone it and will take all reasonable steps to prevent its use within the game.
"We also believe we have a responsibility to educate all our players and are committed to supporting any player who needs help in this area. The ECB board has recently agreed to develop an out-of-competition testing programme to encompass recreational drugs, in co-operation with the Professional Cricketers' Association (PCA).
"These measures will supplement ECB's existing anti-doping programme which involves in- and out-of-competition testing through UK Anti-Doping. The ECB's testing programme applies to all registered county players and up to 200 tests are carried out on average each year. This approximates to around 35-40% of the overall number of registered professional players.
"Last year one player (Abdur Rehman of Somerset) tested positive for cannabis following an in-competition test. England players are tested in addition as part of the ICC's own anti-doping programme for all international cricketers which are also WADA compliant. To date, no England player has tested positive under these programmes."
Surrey have already introduced team-wide anti-drug policy which all players and management are required to abide by. Meanwhile, the PCA, in a statement, have given their backing to the ECB's stance.
It reads "Cricket has a comprehensive anti-doping programme, which has been in place for a number of years. Whilst the focus of this programme is primarily on performance-enhancing drugs, it does include in-competition testing for recreational drugs.
"The PCA is supporting the ECB in its examination of the feasibility of out-of-competition testing for recreational drugs. It confirms its support for such an initiative as long as it is linked to appropriate arrangements for treatment and rehabilitation in the event of a positive test."